Clavulanic Acid for Quitting Smoking
Trial Summary
What is the purpose of this trial?
This research study is looking into the effects of clavulanic on smoking behavior in adult cigarette smokers. The primary study hypothesis is that, compared to placebo, clavulanic acid will reduce smoking over the course of the study.
Research Team
Brett Froeliger, PhD
Principal Investigator
University of Missouri-Columbia
Eligibility Criteria
This trial is for adults aged 18-65 who have been smoking more than 10 cigarettes a day for at least two years and can confirm inhalation. Participants must speak English, have functional vision, and women must test negative in a pregnancy test. They should not use other tobacco or nicotine products during the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either clavulanic acid or placebo for 4 days, with twice-daily oral capsule administration
Follow-up
Participants are monitored for safety and effectiveness after treatment, including fMRI and biochemical assessments
Treatment Details
Interventions
- Clavulanic Acid
- Placebo oral capsule
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Missouri-Columbia
Lead Sponsor